EPS for Galectin Therapeutics, Inc. (GALT) Expected At $-0.13; Thompson Siegel & Walmsley Has Boosted Corning (GLW) Holding By $1.42 Million

April 24, 2018 - By Adrian Erickson

Corning Incorporated (NYSE:GLW) Logo

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.13 EPS on May, 21.They anticipate $0.02 EPS change or 13.33% from last quarter’s $-0.15 EPS. After having $-0.07 EPS previously, Galectin Therapeutics, Inc.’s analysts see 85.71% EPS growth. The stock decreased 6.67% or $0.23 during the last trading session, reaching $3.22. About 202,133 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.90% since April 24, 2017 and is uptrending. It has outperformed by 66.35% the S&P500.

Thompson Siegel & Walmsley Llc increased Corning Inc. (GLW) stake by 89.01% reported in 2017Q4 SEC filing. Thompson Siegel & Walmsley Llc acquired 45,900 shares as Corning Inc. (GLW)’s stock declined 14.33%. The Thompson Siegel & Walmsley Llc holds 97,465 shares with $3.12M value, up from 51,565 last quarter. Corning Inc. now has $22.53B valuation. The stock decreased 3.53% or $0.97 during the last trading session, reaching $26.53. About 7.24 million shares traded. Corning Incorporated (NYSE:GLW) has risen 1.20% since April 24, 2017 and is uptrending. It has underperformed by 10.35% the S&P500.

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by Roth Capital on Thursday, December 7. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Wednesday, June 14. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Buy” rating given on Monday, March 28 by H.C. Wainwright. H.C. Wainwright downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) on Thursday, September 29 to “Neutral” rating. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Mkt Perform” rating given on Monday, October 3 by FBR Capital. Roth Capital maintained the shares of GALT in report on Thursday, January 4 with “Buy” rating. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Monday, September 21. H.C. Wainwright upgraded the shares of GALT in report on Thursday, March 30 to “Buy” rating. On Wednesday, September 28 the stock rating was downgraded by TH Capital to “Sell”. Roth Capital downgraded the stock to “Sell” rating in Wednesday, September 28 report.

Since January 25, 2018, it had 2 insider buys, and 4 sales for $2.67 million activity. CZIRR JAMES C sold $1.33 million worth of stock or 244,444 shares. 2,000 shares valued at $8,191 were bought by FREEMAN KEVIN D on Thursday, February 1. 10X Fund – L.P. had sold 244,444 shares worth $1.33M. 4,000 shares valued at $14,320 were sold by ZUCCONI THEODORE DANIEL on Monday, April 16. CALLICUTT JACK W sold $16,745 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Wednesday, April 4.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $120.98 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Investors sentiment decreased to 0.53 in Q4 2017. Its down 0.14, from 0.67 in 2017Q3. It worsened, as 6 investors sold Galectin Therapeutics, Inc. shares while 13 reduced holdings. 7 funds opened positions while 3 raised stakes. 3.08 million shares or 4.50% less from 3.22 million shares in 2017Q3 were reported. Royal State Bank Of Canada holds 0% or 692 shares in its portfolio. 26,000 were reported by First Republic Invest Mngmt. Moreover, Buckingham Asset Management has 0.01% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Riggs Asset Managment holds 0% or 1,000 shares. Vanguard Group Incorporated reported 915,023 shares or 0% of all its holdings. Pnc Svcs Gp accumulated 51,184 shares. Neuberger Berman Group Inc Limited Company stated it has 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Geode Cap Limited Company has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Susquehanna Intll Group Ltd Liability Partnership stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Da Davidson And holds 0.05% or 688,153 shares in its portfolio. Wells Fargo And Mn holds 0% or 10,882 shares in its portfolio. New York-based Art Advsrs Limited Liability Co has invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Raymond James Associate reported 0% stake. Courage Cap Mgmt Ltd Liability has invested 0.12% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Northern Tru reported 83,668 shares or 0% of all its holdings.

Since October 25, 2017, it had 1 buy, and 3 selling transactions for $7.02 million activity. $66,979 worth of Corning Incorporated (NYSE:GLW) was sold by RIEMAN DEBORAH. TOOKES HANSEL E II sold 6,513 shares worth $205,778. The insider Pambianchi Christine M sold 1,000 shares worth $29,895. On Wednesday, October 25 the insider Musser Eric S sold $945,178. $7.81M worth of stock was sold by WEEKS WENDELL P on Tuesday, October 31. The insider CANNING JOHN A JR bought $887,931.

Investors sentiment increased to 0.84 in 2017 Q4. Its up 0.09, from 0.75 in 2017Q3. It improved, as 41 investors sold GLW shares while 340 reduced holdings. 86 funds opened positions while 234 raised stakes. 598.30 million shares or 2.01% less from 610.60 million shares in 2017Q3 were reported. Bar Harbor Tru owns 3.05% invested in Corning Incorporated (NYSE:GLW) for 180,934 shares. Institute For Wealth Mngmt Ltd Company invested 0.07% in Corning Incorporated (NYSE:GLW). Pacad Limited stated it has 0.29% in Corning Incorporated (NYSE:GLW). Cornerstone Advsr Inc holds 0.05% of its portfolio in Corning Incorporated (NYSE:GLW) for 2,453 shares. Whittier Trust Company, a California-based fund reported 6,954 shares. Loring Wolcott And Coolidge Fiduciary Advisors Ltd Liability Partnership Ma reported 370,545 shares. Dnb Asset As reported 97,495 shares. Murphy Capital Mgmt invested in 16,715 shares or 0.07% of the stock. Creative Planning accumulated 180,072 shares or 0.02% of the stock. Becker Capital Management stated it has 25,708 shares or 0.03% of all its holdings. Thompson Siegel & Walmsley Ltd Company owns 97,465 shares. Covington Management reported 3,309 shares. Timber Hill Limited invested in 48,415 shares. Northwestern Mutual Wealth Com holds 0.01% in Corning Incorporated (NYSE:GLW) or 43,672 shares. Mirador Capital Partners Lp has invested 0.13% in Corning Incorporated (NYSE:GLW).

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>